News | May 21, 2015

Heart Rhythm Society Addresses Three Cardiovascular Disorders Involving the Nervous System

International expert panel provides diagnosis, treatment recommendations for improved quality of care

May 21, 2015 — The Heart Rhythm Society (HRS) has released a first-of-its-kind expert consensus statement on three specific cardiovascular disorders that also involve the autonomic nervous system. The 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. The expert consensus statement was presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.

The expert consensus statement will help front-line cardiologists, arrhythmia specialists and other healthcare professionals to provide care for patients with postural tachycardia syndrome (POTS), inappropriate sinus tachycardia (IST), and vasovagal syncope (VVS).

  • Postural tachycardia syndrome is a clinical syndrome usually characterized by frequent symptoms like lightheadedness, palpitations, fatigue, and clouded thinking that occur when standing.
  • Inappropriate sinus tachycardia is a rapid heart rate greater than 100 beats per minute at rest and associated with distressing symptoms of palpitations.
  • Vasovagal syncope is a syndrome in which people faint, usually when sitting or standing for a while, or exposed to emotional stress, pain or medical settings.

 

The working group aimed to provide simple, clear insights and recommendations about the causes, diagnosis, risk stratification and treatment of these disorders, since recent advances are not widely understood by many healthcare professionals. The document provides evidence-informed recommendations, striking a balance between the need for recommendations and the availability of evidence.

“Each of these disorders causes a variety of symptoms that are challenging for patients, and their healthcare providers need to be able to make the right diagnosis and provide treatment options in a timely manner,” said task force chair and lead author of the statement, Robert S. Sheldon, M.D., Ph.D., FHRS (chair), of Libin Cardiovascular Institute of Alberta in Calgary, Canada. “Our expert consensus statement serves as an accessible, succinct resource for physicians so that diagnosis and treatment for these disorders can be more efficient, and improve both patient care and quality of life.”

The expert consensus group provided definitions and recommendations on the epidemiology and natural history, physiology, diagnosis and treatment for each disorder. Comprehensively, the document:

  1. Establishes working criteria for the diagnosis of POTS, IST and VVS;
  2. Provides guidance and recommendations on assessment and management; and
  3. Identifies key areas in which knowledge is lacking and highlights opportunities for collaborative future research efforts

 

The working group calls for studies to be integrated into daily clinical practice, and for future studies to be performed internationally with networks of investigators to understand the disorders better. Additionally, the group recommends integrating current and cutting-edge technologies into the investigative approaches to the syndromes.

The expert consensus statement was developed in collaboration with and endorsed by the American Autonomic Society (AAS), the American College of Cardiology (ACC), the Asia Pacific Heart Rhythm Society (APHRS), the European Heart Rhythm Association (EHRA), the Pediatric and Congenital Electrophysiology Society (PACES) and the Latin American Society of Cardiac Pacing and Electrophysiology.

For more information: www.hrsonline.org.

Related Content

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Overlay Init